Related Experiment Video
Updated: Aug 11, 2026

Merkel Cell Polyomavirus Infection and Detection
Published on: February 7, 2019
Absence of classical MAP kinase pathway signalling in Merkel cell carcinoma
Roland Houben1, Barbara Michel, Claudia S Vetter-Kauczok
1Klinik und Poliklinik für Haut- und Geschlechtskrankheiten, Julius-Maximilians-University Würzburg, Josef-Schneider-Strasse 2, 97080 Würzburg, Germany. houben_r@klinik.uni-wuerzburg.de
Abstract:
Merkel cell carcinoma (MCC) is a highly metastatic skin tumor. To assess the relevance of the Ras/Raf/MEK/MAP kinase pathway, we analyzed for activating B-Raf mutations and we elucidated the presence of the Raf Kinase Inhibitor Protein (RKIP) and extracellular signal-regulated kinase (ERK) as well as the phosphorylation status of ERK. All MCC samples were negative for the B-Raf(V600E) mutation. Remarkably, RKIP, which was shown to interfere with the activation of MEK by Raf, was highly expressed in primary as well as in metastatic MCC. Immunohistochemical analysis of the phosphorylation status of ERK revealed in 42 out of 44 samples a complete lack of activated ERK in the tumor cells although ERK is expressed; in the two positive cases phosphorylated ERK was restricted to a minor fraction of the tumor cells. Western blot analysis of three MCC-derived cell lines revealed in one case the pattern present in situ (i.e. high RKIP expression and complete absence of phosphorylated ERK). In summary, our data demonstrate the inactivity of the classical MAP kinase signal transduction pathway in MCC, which seems to be because of lack of activation as well as active deactivation. These findings should be accounted for in future therapeutic approaches for this tumor.
Insights
Merkel cell carcinoma (MCC) shows an inactive Ras/Raf/MEK/MAP kinase pathway due to lack of activation and active deactivation. This finding is crucial for developing future MCC therapies.
Area of Science:
- Oncology
- Molecular Biology
- Dermatology
Background:
- Merkel cell carcinoma (MCC) is an aggressive skin cancer with high metastatic potential.
- The Ras/Raf/MEK/MAP kinase pathway is frequently dysregulated in cancers.
- Understanding pathway activity in MCC is vital for targeted therapy.
Purpose of the Study:
- To investigate the role of the Ras/Raf/MEK/MAP kinase pathway in MCC.
- To analyze B-Raf mutations, Raf Kinase Inhibitor Protein (RKIP), and extracellular signal-regulated kinase (ERK) activation in MCC.
Main Methods:
- Analysis of B-Raf mutations (V600E).
- Immunohistochemistry for RKIP expression and ERK phosphorylation.
- Western blot analysis of MCC cell lines.
Main Results:
- No B-Raf (V600E) mutations were detected in MCC samples.
- High RKIP expression was observed in primary and metastatic MCC.
- A significant lack of activated ERK was found in tumor cells, indicating pathway inactivity.
Conclusions:
- The classical MAP kinase pathway is inactive in MCC, likely due to both lack of activation and active deactivation.
- These findings have implications for future therapeutic strategies targeting MCC.
Related Concept Videos
MAPK Signaling Cascades
Interactions Between Signaling Pathways
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Mitogens and the Cell Cycle
Abnormal Proliferation
PI3K/mTOR/AKT Signaling Pathway
